A detailed history of Vanguard Group Inc transactions in Cognition Therapeutics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 1,242,554 shares of CGTX stock, worth $534,298. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,242,554
Previous 1,147,554 8.28%
Holding current value
$534,298
Previous $1.9 Million 69.33%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$0.41 - $2.37 $38,950 - $225,150
95,000 Added 8.28%
1,242,554 $584,000
Q2 2024

Aug 13, 2024

BUY
$1.66 - $2.62 $374,950 - $591,789
225,874 Added 24.51%
1,147,554 $1.9 Million
Q1 2024

May 10, 2024

BUY
$1.78 - $2.53 $356,224 - $506,318
200,126 Added 27.74%
921,680 $1.68 Million
Q4 2023

Feb 14, 2024

BUY
$0.96 - $2.42 $33,271 - $83,872
34,658 Added 5.05%
721,554 $1.33 Million
Q3 2023

Nov 14, 2023

BUY
$1.25 - $1.9 $23,088 - $35,094
18,471 Added 2.76%
686,896 $989,000
Q2 2023

Aug 14, 2023

BUY
$1.56 - $3.38 $39,054 - $84,618
25,035 Added 3.89%
668,425 $1.22 Million
Q1 2023

May 15, 2023

BUY
$1.51 - $2.3 $148,736 - $226,552
98,501 Added 18.08%
643,390 $1.27 Million
Q4 2022

Feb 10, 2023

BUY
$1.17 - $3.51 $168,112 - $504,337
143,686 Added 35.81%
544,889 $1.14 Million
Q3 2022

Nov 14, 2022

BUY
$1.63 - $3.6 $538,361 - $1.19 Million
330,283 Added 465.71%
401,203 $762,000
Q2 2022

Aug 12, 2022

BUY
$1.5 - $3.45 $18,486 - $42,517
12,324 Added 21.03%
70,920 $150,000
Q1 2022

May 13, 2022

BUY
$2.41 - $6.9 $40 - $117
17 Added 0.03%
58,596 $161,000
Q4 2021

Feb 14, 2022

BUY
$5.1 - $12.98 $298,752 - $760,355
58,579 New
58,579 $371,000

Others Institutions Holding CGTX

About COGNITION THERAPEUTICS INC


  • Ticker CGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,710,700
  • Market Cap $9.77M
  • Description
  • Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical tr...
More about CGTX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.